Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bioshield legislation

This article was originally published in The Gray Sheet

Executive Summary

Sen. Judd Gregg (R- N.H.) plans Senate HELP Committee hearings this fall to consider follow-up legislation to the Project Bioshield Act (S 15) to address, among other topics, corporate liability for products developed under the program. The legislation, approved in the House July 14 following Senate passage May 19, secures $5.6 bil. in funding over the next five years for development of diagnostic and therapeutic countermeasures against bioterrorism agents and ensures rapid regulatory review, when necessary. AdvaMed has backed the Bioshield provisions since the concept was unveiled during President Bush's 2003 State of the Union address. The association also has maintained the importance of liability protection for products used in emergency...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel